Clinical Trials

Key Inclusion Criteria:

- Clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic
Criteria within 2 years of the Screening Visit, inclusive, and at least 30 years of
age at the time of diagnosis.

- Modified Hoehn and Yahr scale stages 1 to 2 (in OFF state), inclusive, at screening.

- MDS-UPDRS Parts II and III (in OFF state) combined score ≤ 40
at screening.

- Screening genetic test results verifying the absence of a pathogenic leucine-rich
repeat kinase 2 (LRRK2) variant. Confirmation of this eligibility requirement may come
from an accredited genetic test that includes all exclusionary LRRK2 genetic variants.

Key Exclusion Criteria:

- Clinically significant neurological disorder other than PD, including but not limited
to stroke, dementia, or seizure, within 5 years of screening visit, in the opinion of
the Investigator.

- Clinical evidence of atypical parkinsonism (e.g., multiple-system atrophy or
progressive supranuclear palsy) or evidence of drug-induced parkinsonism.

- Montreal Cognitive Assessment (MoCA) score < 24 at the screening visit.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 10/27/22. Questions regarding updates should be directed to the study team contact.